About Half of Women May Benefit From Mammograms at 40

Share this content:
About Half of Women May Benefit From Mammograms at 40
About Half of Women May Benefit From Mammograms at 40

FRIDAY, April 15, 2016 (HealthDay News) -- New research suggests that all women turning 40 should get a breast cancer risk assessment, since half of them may have risks that are high enough to warrant annual mammograms right away. The findings were presented at the annual meeting of the American Society of Breast Surgeons (ASBS), held from April 13 to 17 in Dallas.

The new study involved 909 women, none of whom had been diagnosed with breast cancer. All were seen as new patients at the Massachusetts General Hospital breast clinic between March 2011 and October 2015, the researchers said.

Fifty percent of these women met either the American Cancer Society (ACS) or the ASBS requirements for early mammography, lead researcher Jennifer Plichta, M.D., breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston, told HealthDay. That includes 39 percent who met the ACS criteria for above-average risk for breast cancer, and an additional 11 percent who met the ASBS criteria. The researchers also found that 32 percent of the women met the groups' eligibility standards for regular screening magnetic resonance imaging, and 25 percent would be eligible for genetic testing.

Breast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted. Since the new guidelines lean heavily on knowing breast cancer risk, doctors need to redouble their efforts to make sure risk assessments are done for women in their early 40s, they concluded.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths